Gossamer Bio Statistics
Total Valuation
Gossamer Bio has a market cap or net worth of $551.71 million. The enterprise value is $533.58 million.
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Gossamer Bio has 229.88 million shares outstanding. The number of shares has increased by 4.01% in one year.
| Current Share Class | 229.88M |
| Shares Outstanding | 229.88M |
| Shares Change (YoY) | +4.01% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 3.56% |
| Owned by Institutions (%) | 61.42% |
| Float | 185.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.41 |
| Forward PS | 20.40 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.40
| Current Ratio | 4.40 |
| Quick Ratio | 4.11 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.28 |
Financial Efficiency
Return on equity (ROE) is -783.37% and return on invested capital (ROIC) is -41.64%.
| Return on Equity (ROE) | -783.37% |
| Return on Assets (ROA) | -29.63% |
| Return on Invested Capital (ROIC) | -41.64% |
| Return on Capital Employed (ROCE) | -77.74% |
| Revenue Per Employee | $277,497 |
| Profits Per Employee | -$956,848 |
| Employee Count | 145 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.54M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +155.89% in the last 52 weeks. The beta is 1.95, so Gossamer Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.95 |
| 52-Week Price Change | +155.89% |
| 50-Day Moving Average | 2.53 |
| 200-Day Moving Average | 1.54 |
| Relative Strength Index (RSI) | 44.64 |
| Average Volume (20 Days) | 3,667,926 |
Short Selling Information
The latest short interest is 27.40 million, so 11.92% of the outstanding shares have been sold short.
| Short Interest | 27.40M |
| Short Previous Month | 23.99M |
| Short % of Shares Out | 11.92% |
| Short % of Float | 14.79% |
| Short Ratio (days to cover) | 5.51 |
Income Statement
In the last 12 months, Gossamer Bio had revenue of $40.24 million and -$138.74 million in losses. Loss per share was -$0.61.
| Revenue | 40.24M |
| Gross Profit | 40.24M |
| Operating Income | -145.62M |
| Pretax Income | -142.29M |
| Net Income | -138.74M |
| EBITDA | -145.29M |
| EBIT | -145.62M |
| Loss Per Share | -$0.61 |
Full Income StatementBalance Sheet
The company has $212.92 million in cash and $202.83 million in debt, giving a net cash position of $10.09 million or $0.04 per share.
| Cash & Cash Equivalents | 212.92M |
| Total Debt | 202.83M |
| Net Cash | 10.09M |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | -46.11M |
| Book Value Per Share | -0.20 |
| Working Capital | 182.30M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$154.30 million and capital expenditures -$79,000, giving a free cash flow of -$154.38 million.
| Operating Cash Flow | -154.30M |
| Capital Expenditures | -79,000 |
| Free Cash Flow | -154.38M |
| FCF Per Share | -$0.67 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -361.91% |
| Pretax Margin | -353.62% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Gossamer Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.01% |
| Shareholder Yield | -4.01% |
| Earnings Yield | -25.52% |
| FCF Yield | -28.40% |
Analyst Forecast
The average price target for Gossamer Bio is $8.60, which is 258.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.60 |
| Price Target Difference | 258.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 30.76% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gossamer Bio has an Altman Z-Score of -8.25. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.25 |
| Piotroski F-Score | n/a |
